CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Select Therapeutics Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Select Therapeutics Inc.
50 Cummings Park
Phone: (617) 520-6693p:617 520-6693 Woburn, MA  1801  United States
This company is no longer actively traded on any major stock exchange.
Business Summary
Select Therapeutics Inc. is engaged in the development of novel pharmaceutical treatments, utilizing technologies licensed from academic institutions. The Company is active in two related areas of the development of novel and proprietary cytotoxic and immunotherapeutic agents for the treatment of cancers and infectious diseases. The Company's proprietary targeted cytotoxic compound under development for the treatment of cancers bearing certain cell surface receptors is VeroPulse. A general platform technology under development uses modified natural agents to inject the immune system with the chemical signature of diseases to be combated as therapeutic vaccines. Activate and VeroVax are the Company's proprietary vaccine technologies designed to facilitate the delivery of antigens to dendritic cells for enhanced immune stimulation via a novel targeting and delivery route. The Company's products are in various phases of research and development.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-------

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20026/30/2001-Yes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
2835 In vitro and in vivo diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board AndrewMuir 57 5/20/2002 9/1/2001
President, Chief Executive Officer, Director Craig A.Sibley 42 5/20/2002 12/1/1996
Senior Vice President of Clinical and Regulatory Affairs DouglasMcNair 48 10/1/2001 10/1/2001
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 27 (As of 9/13/2001)
Outstanding Shares: 17,560,499 (As of 5/10/2002)
Shareholders: 244
Stock Exchange: OTC
Federal Tax Id: 980169105


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023